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Viruses are implicated in the initiation or ﬂare of graft-versus-host disease (GVHD) by virtue of their ability to
activate antigen-presenting dendritic cells (DC). Herpes simplex virus (HSV) infects circulating CD34þ stem
cell progenitors, favoring their differentiation into skin homing DC (CD1aþ Langerhans cells) that contribute
to the development of an inﬂammatory skin rash known as HSV-associated erythema multiforme (HAEM).
Following on these ﬁndings, we conducted a prospective study to examine whether HSV is also associated
with GVHD. Skin biopsies and peripheral blood mononuclear cells (PBMC) were collected from 37 consecutive
patients on admission before and after allogeneic hematopoietic stem cell transplantation (HSCT) and
examined for HSV antigen (Pol) expression and the presence of PolþCD34þ and PolþCD1aþ cells. Sixteen
patients developed a skin rash that was histopathologically consistent with GVHD (group I), 3 patients had
a rash that was not GVHD (group II, EM-like) and 18 patients did not develop any rash after HSCT (group III).
Skin biopsies from the group I patients were Pol negative pre-HSCT (baseline) but became Polþ after the
diagnosis of GVHD. The GVHD biopsies also contained PolþCD34þ and PolþCD1aþ cells, and these patients
had a signiﬁcant percentage of circulating PolþCD34þ and PolþCD1aþ PBMC. By contrast, the group II
patients had Polþ skin cells and PolþCD34þ circulating PBMC at baseline that decreased post-HSCT. The
group III patients had Pol negative skin and very few circulating PolþCD34þ and PolþCD1aþ PBMC at
baseline that were not signiﬁcantly changed post-HSCT. The data associate skin GVHD with HSV reactivation
during conditioning and its propensity for nonreplicative infection of CD34þ PBMC that induces DC activa-
tion. Further studies are needed to better elucidate this association.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Activation of host dendritic cells (DC) by tumor necrosis
factor-alpha, interleukin-1, and lipopolysaccharide released
from tissues damaged during high-intensity conditioning
regimens and the resulting enhanced presentation of histo-
compatibilty antigens to donor T cells is a ﬁrst step in the
development of acute graft-versus-host disease (GVHD) [1].
Viruses reactivated during the immunosuppressive period
before and after allogeneic transplantation increase the risk
of GVHD [2]. The ubiquitous herpes viruses, cytomegalovirus
(CMV), Epstein-Barr virus, and human herpes virus 6 or 7
(HHV-6, -7) might participate in the induction of GVHD [3].
CMV infections that occur after but not before day 120 after
cord blood transplantation, along with Epstein-Barr viremia
and adenoviral enteritis, can develop in the context of GVHD
[4], and DC activation via CMV-stimulated Toll-like receptor
9 (TLR9) is an established mechanism for this virus’ contri-
bution to the GVHD reaction [5].
Our studies follow on previous ﬁndings that herpes
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12.12.021(CD1aþ) that contribute to the development of HSV-
associated erythema multiforme (HAEM) through T cell
stimulation. Indeed, HAEM develops after a preceding
primary or recurrent HSV episode, whether clinical or
subclinical, but it is independent of virus replication. HAEM
lesions are free of infectious virus, but they contain viral
DNA fragments as determined by polymerase chain reaction
(PCR) [6-14]. Direct comparison of similarly sensitive primers
for 9 genes located along the entire length of the HSV
genome revealed that most of the viral DNAwas lost, but 70%
to 75% of the patients retained viral DNA sequences that
included the HSV gene UL30, which codes for viral DNA
polymerase (Pol) [14-16]. Lesion development was associ-
ated with viral DNA expression (including Pol RNA and Pol
protein), which was not seen in healed lesions, even if they
were still positive for viral DNA [8,14,17-20]. Skin-delivered
viral antigen was shown to cause HAEM [21]. Consistent
with the limited spectrum of viral antigens expressed in the
HAEM lesions, the HSV-speciﬁc T cell repertoire is restricted,
but the dominant CD4þ/Vb2 cells inﬁltrate the skin early
after lesion onset and produce the inﬂammatory cytokine
interferon-gamma (IFN-g) [15,18,22]. This is followed by
the recruitment of autoreactive T cells [15], apparently in
response to cellular genes driven by the transcription factor
SP-1, which is induced by Pol through molecular mimicry
with a negative SP-1 regulator [23].Transplantation.
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nity [24-26] and increased expression of cytokines and/or
chemokines was reported in both virus and drug-induced
erythema multiforme (EM) skin lesions [22,27]. In HAEM,
viral DNA is fragmented in infected blood CD34þ cells and
they are encouraged to differentiate into Langerhans cells
(LC) that transport the viral DNA fragments to the skin
[13,28]. Because (1) HSV DNA stimulates TLR9 [29], which is
associated with the contribution of CMV to GVHD [5], and (2)
GVHD develops after the infusion of peripheral blood CD34þ
cells, we considered the possibility that HSV could contribute
to GVHD development through a mechanism similar to that
implicated in HAEM. This hypothesis is supported by
a retrospective study, which showed that Pol was expressed
in biopsies from a high proportion (79%) of patients with
acute skin GVHD [30]. Here we report the results of
a prospective study, which demonstrates that acute skin
GVHD lesions are positive for Pol and contain PolþCD34þ
and PolþCD1aþ cells that are not seen in the pre-
transplantation skin samples obtained from the same
patients. This likely involves nonreplicative (incomplete)
infection of donor CD34þ cells by virus reactivated during
immunosuppressive conditioning.
STUDY SUBJECTS
This prospective study enrolled adult patients with
various hematologic malignancies who underwent alloge-
neic hematopoietic stem cell transplantation (HSCT) from
related or unrelated donors. After obtaining informed
consent, baseline blood samples (30 mL) and 4 mm skin
punch biopsies were obtained from all the study subjects on
the same day during the early phase of the conditioning
regimen and before stem cell infusion. Second skin biopsies
were obtained when the patients developed skin rash before
or within 48-72 hours of steroid treatment. GVHD diagnosis
was made by appropriate clinical presentation and
conﬁrmed histologically. The same biopsy samples were
evaluated for the GVHD diagnosis, Pol antigen expression,
and the inﬁltration by Polþ mononuclear cells in 2 separate
laboratories. A third biopsy was collected from 6 patients
with a rash diagnosed as GVHD that showed increased
clinical severity to evaluate the potential relationship
between the levels of Pol expression and clinical severity.
Second blood samples were collected from all patients after
HSCT on the same day that the second skin biopsies were
obtained. For uniform assessment, second blood samples
were collected from the nonrash patients at the time of
myeloid recovery post-HSCT (between days þ14 to þ28)
when most acute GVHD occurs.
MATERIALS AND METHODS
Antibodies
The generation and HSV speciﬁcity of the Pol antibody were previously
described. The antibody speciﬁcally identiﬁes the Pol protein in HSV-
infected cells, but it does not recognize cellular epitopes in uninfected
cultured cells or patient tissues by immunohistochemistry or immuno-
blotting [8,14-18,22,23,30]. Antibody to the major HSV capsid protein
VP5 was obtained from Virusys Corp (Sykesville, MD) and used to detect
virion formation as a result of virus replication. Polyclonal rabbit antibody
to human E-cadherin, unconjugated and ﬂuorescein (FITC)-conjugated
monoclonal antibodies (MAb) to human CD14, and unconjugated MAb to
human CD1awere obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
FITC-conjugated MAbs to human CD1a and CD3 as well as FITC-conjugated
and unconjugated MAb to human CD34 were obtained from BD Biosciences
(San Diego, CA). Alexa-Fluor 594econjugated goat anti-mouse IgG (used to
detect anti-CD34, -CD14, and -CD1a in the skin) and Alexa-Fluor
488econjugated goat anti-rabbit IgG (used to detect anti-Pol in the skin)were obtained from Invitrogen (Molecular Probes, Eugene, OR). Biotin anti-
mouse/human CD11b antibody was obtained from Leinco Technologies, Inc.
(St. Louis, MO), and Texas Red Streptavidin (Vector Laboratories, Burlingame,
CA) was used to detect it. APC-conjugated goat anti-rabbit IgG antibody
(F(ab’)2-speciﬁc) was purchased from Imgenex (San Diego, CA) and used in
FACS analysis.
Protein Extraction and Immunoblotting
Biopsies were transferred to test tubes containing approximately
10 sample volumes of RIPA buffer (20 mM Tris-HCl [pH 7.4], .15 mM NaCl,
1% Nonidet P-40 [Sigma, St. Louis, MO], .1% sodium dodecyl sulfate [SDS,
BioRad, Hercules, CA], .5% sodium deoxycholate supplemented with
protease, and phosphatase inhibitor cocktails [Sigma]) and incubated for 30
minutes on ice in an attempt grossly the tissue specimens with the help of
a plastic mortar. Samples were thereafter sonicated for 60 seconds at 25%
output power using the Sonicator/Ultrasonic Processor (Misonix Inc.,
Farmingdale, NY). Total protein was determined by the bicinchoninic
assay (Pierce, Rockford, IL). Proteins were resolved by SDS-PAGE and
transferred to Immobilon-P (Millipore, Billerica, MA, USA) membranes. Non
speciﬁc binding was blocked by incubation (1 hour, 25 C) in TNT buffer
(.01 M Tris-HCl [pH 7.4], .15 MNaCl, .05% Tween 20) containing 5% bovine
serum albumin, and the blots were exposed (overnight; 4 C) to primary
antibodies followed by secondary antibodies conjugated to horseradish
peroxidase (Cell Signaling Technologies, Beverly, MA). Detection was with
ECL reagents (Amersham Life Science, Arlington Heights, Illinois) followed
by exposure to a high-performance chemiluminescence ﬁlm (Hyperﬁlm
ECL, Amersham Life Science), as described [28].
Immunoﬂuorescent Staining of Skin Tissues
Indirect immunoﬂuorescent staining was with Pol or VP5 antibodies
and differentially labeled secondary antibodies. Normal IgG served as
control. Duplicate sections were stained by double immunoﬂuorescence
with antibodies to Pol and to the respective cell markers CD34þ, CD1a,
CD14, or CD11b. Brieﬂy, sections (5 mm) of parafﬁn-embedded tissues were
deparafﬁnized in xylene and decreasing ethanol gradients, washed in
phosphate-buffered saline (PBS), and subjected to antigen retrieval using
Retrievagen A (pH 6.0) (BD Biosciences) in a 95C water bath for 10 minutes.
Slides were allowed to cool in Retrievagen solution (20 minutes at 25C),
washed with PBS, and blocked (1 hour at 25C) in blocking buffer (5% bovine
serum albumin [BSA] and 5% normal goat serum [NGS] in PBS). Tissue
sections were incubated with primary antibodies (18 hours at 4C) in
blocking buffer, washed with .1% Tween-20 in PBS, and exposed to
secondary antibody (1 hour at 25C). The sections were washed, mounted in
Slowfade Gold antifade reagent with DAPI (Invitrogen), and visualized with
a Nikon (Nikon Inc., Melville, NY) E4100 ﬂuorescent microscope utilizing
FITC (330 to 380 nM) and UV (DAPI) (465 to 495 nM) cubes. Cells were
counted in 5 randomly selected 3mm2 ﬁelds (250 cells each), and the
percent staining cells was calculated relative to total cell numbers deter-
mined by DAPI staining. The mean percentage of positive cells in each
comparison group was calculated by dividing the total number of positive
cells by the total number of patients in the group.
PCR Ampliﬁcation
DNA was extracted from formalin-ﬁxed parafﬁn-embedded biopsies
and PCR ampliﬁed with primers for Pol and control human b-globin, as
described [7,17,18].
Flow Cytometry Analysis (FACS)
FACS analysis was done as previously described [18,28]. Peripheral
blood mononuclear cells (PBMC) were collected by Ficoll-Paque PLUS
density gradient centrifugation (GE Healthcare, Piscataway, NJ) according to
the manufacturer’s instructions, and 2-5  106 cells in a total volume of 100
mL of 2% FACS buffer (2% fetal bovine serum [FBS] in PBS) were stained in
double immunoﬂuorescence with antibodies to Pol or E-cadherin and
cellular markers. The cells were washed in PBS, ﬁxed in 1% para-
formaldehyde in PBS, and stored at 4C in the dark until analysis. Controls
consisted of unstained cells, cells stained with FITC-conjugated istoype-
matched antimouse IgG1 alone or with APC-conjugated goat antirabbit IgG,
and cells stained only with secondary antibodies or CD3, CD34, or Pol
antibodies. Two-color FACS analysis was performed using the FACScan and
LSRII analytical ﬂowcytometers (both from Becton Dickinson Immunocy-
tometry Systems, San Jose, CA). FITC-labeled cells were excited with a 488
nm blue laser and measured using a 530/30 nm band pass ﬁlter. Alexa 633
ﬂuorescence was excited with a 633 nm red laser and measured with a 660/
20 nm band pass ﬁlter. After gating with the respective isotype matched
immunoglobulin, percentages of positive stained cells and mean ﬂuores-
cence calculations were determined from the histogram and dot plot
Table 1
Patient Characteristics
Characteristics of Patients Rash with GVHD No Rash EM-Like Rash without GVHD
Number of patients 16 18 3
Age at transplantation, median (range) 52 (27 to 64) 50 (23 to 62) 50 (28 to 64)
Male gender 10 8 3
Underlying disease
Acute myelogenous leukemia 4 4 1
Myelodysplastic syndrome 4 3 -
Acute lymphoblastic leukemia - 2 -
Non-Hodgkin lymphoma 2 - 2
Hodgkin lymphoma 3 1 -
Chronic lymphocytic leukemia 1 2 -
Multiple myeloma 2 1 -
Aplastic anemia - 2 -
Chronic myelogeneous leukemia - 1 -
Myeloproliferative disorders - 1 -
Plasmacytoid dendritic cell neoplasm - 1 -
Conditioning regimen
Myeloablative 8 7 3
Cyclophosphamide þ TBI 2 2 -
Melphalan þ TBI - 4 2
Busulfan þ Fludarabine 4 1 1
Others 2 - -
Reduced-intensity 8 11 -
Busulfan þ ﬂudarabine 7 5 -
Melphalan þ ﬂudarabine 1 4 -
Others - 2 -
HLA-mismatch (7 of 8) transplant 2 5 2
Donor type
Related 5 10 1
Unrelated 11 8 2
Male 11 11 2
Donor/recipient sex match (%)
MaleeMale 8 4 2
MaleeFemale 3 7 -
FemaleeMale 2 4 1
FemaleeFemale 3 3 -
GVHD prophylaxis
Tacrolimus þ methotrexate 12 13 3
Tacrolimus þ mycophenolate 4 2 -
Tacrolimus þ sirolimus 0 3 -
Tacrolimus þ antithymocyte globulin  other 4 3 2
Extracutaneous GVHD
Gastrointestinal system 8 n/a n/a
Liver 2 n/a n/a
GVHD indicates graft-versus-host disease; EM, erythema multiforme; TBI, total body irradiation.
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cells were to the right of that marker. The numerical value (%) from the
quadrant that reﬂects the double-positive cells in the control (APC-conju-
gated IgG and FITC-conjugated istoype-matched IgG1) was subtracted from
the experimental values of the same quadrant for all patients and at all time
points. The percent of cells in the speciﬁc antibody-stained samples was
calculated using the FlowJo (Tree Star Inc., Ashland, OR, USA).
Statistical Analyses
Data were analyzed by between-group analysis of variance (ANOVA)
and mixed repeated-measures ANOVAs followed by the Tukey’s post hoc
tests. Analyses were performed with SigmaPlot 11.2 for Windows (Systat
Software, Point Richmond, CA). Data were also analyzed by exact nonpara-
metric rank test. Two group comparisons were performed using the
Wilcoxon signed rank (paired samples, eg, rashwith GVHD and rashwithout
GVHD) test.
RESULTS
Patients and HSCT
The study was conducted between 2008 and 2010 at the
University of Maryland Marlene and Stewart Greenebaum
Cancer Center. Patients were enrolled in the study after
hospitalization for an allogeneic HSCT using donor periph-
eral blood CD34þ cells collected by apheresis after G-CSF
mobilization. Patient characteristics are summarized inTable 1. All the patients and donors were HSV seropositive
(HSV-1 and/or HSV-2) as determined by ELISA. Patients had
to be in hematologic remission after chemotherapy before
receiving immunosuppressive conditioning regimen with or
without total body irradiation. Patients received myeloa-
blative or nonmyeloablative HSCT. Some patients received
total body irradiation and others received chemo-only
conditioning regimen. Tacrolimus-based GVHD prophylaxis
was started on day 3, before infusion of donor stem cells.
Antimicrobial prophylaxis, including acyclovir for HSV at
800 mg twice a day by mouth, was started on day 3 post-
transplantation and continued throughout the follow-up.
Histologic evidence provided by the pathology service was
used for diagnosis of GVHD in the appropriate clinical
presentation.
A total of 37 allogeneic HSCT recipients were enrolled in
the study. Nineteen patients (51%) developed skin rash
during the post-HSCT period. Sixteen of these 37 patients
(43%) were diagnosed with GVHD within 8 to 244 days
(median, 26 days) post-HSCT (group I, rash with GVHD). The
rash seen in the other 3 patients (8%) was pathologically
inconsistent with GVHD and it developed within 16 to 24
days (median, 16 days) post transplantation (group II; rash
Figure 1. (A) Representative immunoblotting of protein extracts from GVHD (patients JP, MD), HAEM (patient SA) and HSV (patient MB) lesions with antibody to Pol
followed by GAPDH antibody (loading control) after blot stripping. An extract of HSV-2 infected Vero cells was used as control. The levels of Pol protein in the
different tissues reﬂect both the total amount of protein loaded on the gel (lower GAPDH levels in tissues than cultured cells) and the intensity of gene expression, as
evidenced for patient JP who had lower Pol levels than the other patients, although the levels of GAPDH were higher. (B) Representative immunohistochemical
staining of Polþ and VP5þ skin cells in HSV-2epositive genital lesion (patient MB) using indirect immunoﬂuorescence with antibodies to Pol, VP5 or normal IgG
control, and Alexa-Fluor 488econjugated goat anti-rabbit IgG (red). Pol staining is both cytoplasmic and intranuclear (arrow). DAPI staining to identify cell nuclei is
blue. (C) Representative PCR of DNA extracted from GVHD and HAEM lesions and normal skin from patients JP and SA.
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group II) developed late GVHD (>130 days post-HSCT) and
were treated with the CMV drug Cytovene(R), ganciclovir
sodium IV (Roche Laboratories, Nutley, NJ) before the second
biopsy was obtained. Eighteen patients (49%) never devel-
oped rash (group III, no rash). The median ages were 52, 50,
and 50 years for the patients in groups I, II, and III, respec-
tively. Ten patients (55%) in the group III received HLA-match
related donor allogeneic HSCT. Eleven patients (69%) in the
GVHD group received unrelated donor transplant. HLA-
mismatch (7/8) was present in 2 patients in group I, 2
patients in group II, and 5 patients in group III. The majority
of the patients with GVHD had 100% donor chimera.
All patients were lesion-free when the pre-HSCT blood
sample and skin biopsy were taken, in a median 4 days
before transplantation, ranging from 2 to 6 days. Post
transplantation skin biopsies were taken when the patients
developed skin rash, before or within 48-72 hours of steroid
treatment. They were histopathologically diagnosed as
GVHD grade I (6 patients), GVHD grade II (5 patients), and
GVHD grade III (5 patients). In 6 patients diagnosed as GVHD
grades I or II, an additional post-HSCT skin biopsy was ob-
tained at the time of increased rash severity, deﬁned as
diffuse erythema involving more than 50% of body surface
area, blistering maculopapular rash, skin breakdown or
sloughing, and a histopathological classiﬁcation of GVHD
grade III in 4 of them. Post-HSCT blood samples were
collected on average twice (ranging from 2 to 4 times) during
the hospitalization.
Control Subjects
The following patients served as controls: (1) Two non-
transplant and 1 study cohort (MB) patient with culture-
positive HSV lesions, including 1 with buttock lesions(HSV-1), 1 with vulvar lesions (HSV-2), and 1 (MB) with
acyclovir-resistant HSV-2 genital ulcers erupted on day 5
post-HSCT before she developed skin GVHD at other body
sites; (2) 3 patients with skin GVHD who received acyclovir
prophylaxis initiated on day 3 post-HSCT according to
protocol, and 1 nontransplantation patient with HAEM from
whom biopsies were obtained from the respective skin
lesions as well as the adjacent uninvolved skin; and (3) 2 HSV
seronegative subjects who provided peripheral blood
mononuclear cells.
The virus positive tissues from all 3 HSV patients were Pol
positive by immunoblotting and immunoﬂuorescence, as
shown for 1 of them in Figure 1A and B, respectively. These
tissues also stainedwith antibody to themajor capsid protein
VP5, which is indicative of virus replication, but not with
normal IgG (Figure 1B). Intracellular localization was as
described for patients with culture-conﬁrmed HSV lesions,
including those that occur post-HSCT [30]. Pol and VP5
staining was seen in the epidermis and the dermal surface of
the lesion base, and it primarily localized in the cytoplasm
(Pol, VP5) and cell nucleus (Pol) (Figure 1B). Consistent with
previous ﬁndings [6-20,30], the GVHD and HAEM tissues
from our control subjects were free of infectious virus by
culture, but they retained Pol DNA, as shown for 2 of these (JP
and SA) in Figure 1C. They expressed the Pol protein
(antigen), as determined by immunoblotting and shown for
3 of the patients (JP, SA, and MD) in Figure 1A. The normal
tissues from these patients were free of Pol DNA (Figure 1C)
and protein, and the Pol antibody did not stain the PBMC
from the seronegative subjects (data not shown). The data
conﬁrm the previously established speciﬁcity of the Pol
antibody [8,14-18,22,23,30] and further document its ability
to identify the Pol antigen. Expression of other HSV antigens
is not excluded, but it was not studied.
Figure 2. Representative images of immunohistochemical staining of tissues collected pre- and post-HSCT. (A) Representative skin biopsies collected at baseline from
2 patients (#1 and #2) and stained with antibodies to Pol or Pol and CD34 and secondary antibodies that are labeled with FITC (Pol; green) or Alexa-Fluor 488 (CD34;
red) are signal negative. Representative biopsy of post-HSCT GI (colon) GVHD lesion from patient #1 stained with antibodies to Pol and CD34 and secondary
antibodies that are labeled with FITC (Pol; green) or Alexa-Fluor 488 (CD34; red) is signal negative. (B) Representative biopsies of post-HSCT skin GVHD lesions from
patients #1 and # 2 stained with antibodies to Pol, VP5, or Pol and cellular markers CD34 or CD1a, and secondary antibodies that are labeled with FITC (Pol, VP5;
green) or Alexa-Fluor 488 (CD34, CD1a; red). Antigen co-localization is yellow. DAPI staining to identify cell nuclei is blue.
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Skin ﬁndings
Skin data are available for 15 of 16 patients with GVHD
and representative staining patterns of the skin biopsies
from these patients are shown in Figure 2. Pol staining was
not seen in the epidermis or dermis from 13 patients (87%)
pre-HSCT. The other 2 patients had low numbers of Polþ cells
in the epidermis (8.5% and 15.6%), presumably reﬂecting
virus reactivation from latency that occurred during the
conditioning treatment. By contrast, the post-HSCT GVHD
biopsies from all 15 patients had high numbers of Polþ skin
cells, with one-half of the epidermal cells (mean, 49.7% 
6.8%) and one-third of the dermal cells (mean, 24.6%  3.5%)
being Polþ (Table 2, Figure 3). The percentage of Polþ cells
was also signiﬁcantly increased in the 2 patients who had
positive epidermal staining at baseline (78.8% and 32.6%,respectively). The difference in the percent of Polþ cells pre-
and post-HSCT was highly signiﬁcant (P < .001 by ANOVA).
Further supporting the relationship between HSV gene
expression (Pol) and disease, the percentage of Polþ cells
was strongly correlated with lesion severity, as determined
in 6 patients for whom biopsies were obtained both early
after lesion development and at a later time when the
severity of the skin rash was signiﬁcantly increased. In these
patients the percentage of Polþ cells in the more severe
GVHD biopsies was 3- to 68-fold higher than in the early
GVHD biopsies for the epidermis and 2- to 52-fold higher for
the dermis. The GVHD biopsies did not stain with VP5 anti-
body, and the Pol staining was strictly cytoplasmic (Figure 2).
This was also reported for HAEM and is indicative of
nonreplicative (incomplete) infection associated with viral
DNA fragmentation [6-18,23,30]. It is in contrast to the
Table 2
Mean percentage  SEM of Positive Cells by Immunoﬂuorescent Staining in Pre- and Post transplant Samples
Marker(s) for HSV and Cell Types Rash with GVHD P Value No Rash after HSCT P Value EM-Like Rash without
GVHD
P Value
Pre-HSCT Post-HSCT Pre-HSCT Post-HSCT Pre-HSCT Post-HSCT
Skin n ¼ 15 n ¼ 16 n ¼ 3
Polþ cells in epidermis 1.6  1.2 49.7  6.8 <.001 0 n/a d 47.5  23 4.1  1.1 .1
Polþ cells in dermis .1  .1 24.6  3.5 <.001 0 n/a d 8.1  6.9 .3  .3 .3
CD34þPolþ 0 5.9  2.8 .04 0 n/a d 0 3.0  2.6 .3
CD14þPolþ 0 3.9  2.2 .08 0 n/a d 0 0 d
CD11bþPolþ 0 7.8  6.2 .2 0 n/a d 0 0 d
CD1aþPolþ 0 15.5  6.8 .03 0 n/a d 0 0 d
Blood n ¼ 13 n ¼ 16 n ¼ 3
CD34þPolþ .8  .3 3.7  1.1 .02 2.5  .9 1.5  .4 .3 3.2  .7 1.0  .8 .1
CD34þE-cadþ .6  .3 5.3  2.3 .05 1.5  .4 .9  .2 .2 3.4  .9 2.1  .5 .3
CD14þPolþ 9.1  3.5 32.2  5.9 .002 11.2  4.0 15.0  2.9 .4 26.6  9.1 4.3  3.5 .08
CD1aþ/Polþ .8  .4 7.9  3.0 .02 3.0  1.4 1.6  .6 .4 2.3  1.3 1.3  1.3 .6
HSV indicates herpes simplex virus; GVHD, graft-versus-host-disease; EM, erythema multiforme; HSCT, hematopoietic stem cell transplantation.
G. Akpek et al. / Biol Blood Marrow Transplant 19 (2013) 529e537534HSV-lesional skin, which also stained with VP5 antibody and
had both cytoplasmic and intranuclear Pol localization
associated with viral DNA replication (Figure 1).
To test the hypothesis that the potential contribution of
HSV to skin GVHD is through pathogenesis strategies similar
to those involved in HAEM, the skin tissues were examined
for CD34þ and CD1aþ cells that express Pol (PolþCD34þ
and PolþCD1aþ) by double immunoﬂuorescent staining.
The pre-HSCT skin tissues from all 15 patients were free of
inﬁltrating Polþmononuclear cells (CD34þ, CD14þ, CD11bþ
or CD1aþ), but PolþCD34þ cells (mean, 5.9%  2.7%) and
PolþCD1aþ cells (mean, 15.5% 8.7%) were seen in the post-
HSCT GVHD biopsies from 8 of 15 and 6 of 13 patients,
respectively. These differences were statistically signiﬁcant
(P ¼ .042 and P ¼ .033 by ANOVA, respectively), associating
GVHD lesions with inﬁltration by CD34þ cells and LC that are
positive for HSV antigen. The PolþCD34þ and PolþCD1aþ
cells were primarily detected in the dermis, but rare
PolþCD1aþ cells were also seen in the epidermis (Figure 2).
The CD34þ and CD1aþ cells did not stain with VP5 antibody
(data not shown) consistent with previous ﬁndings that they
do not support virus replication and are the site of viral DNAFigure 3. Bar graphs in the top 2 panels show the percentage of Polþ cells in the epi
(group I) or EM-like rash with no GVHD (group II) pre- (blue bar) and post- (red bar) H
immunostaining for Pol and cellular markers. PolþCD14þ, PolþCD11bþ, PolþCD1aþ, a
HSCT from patients with GVHD are shown. *, **, and *** represent P values calculatefragmentation [28]. Three patients had increased numbers of
Polþ monocytes (CD14þ and CD11bþ) in the post-HSCT
biopsies compared with pre-HSCT biopsies, but for most of
the other patients, the percentage of Polþ monocytes in the
pre-HSCT biopsies relative to post-HSCT biopsies was similar
(Table 2, Figure 3). Signiﬁcantly, 10 patients also developed
extracutaneous GVHD, 8 of them in the gastrointestinal
system and 2 in the liver (Table 1). However, biopsies
collected from the colon, stomach, and esophagus GVHD
lesions from these patients did not stain with Pol antibody
and did not contain Polþ CD34þ or PolþCD1aþ cells
(Figure 2A), suggesting that the association of HSV with
GVHD is restricted to the skin.
Blood ﬁndings
The ability of PBMC to transport HSV antigens is estab-
lished [13,27] but the contribution of CD34þ cells is still
minimally documented. Data regarding the presence of Pol
in circulating CD34þ PBMC are available for 13 patients in
this group (Table 2, Figure 4). The percentage of PolþCD34þ
cells was minimal at baseline, essentially reﬂecting back-
ground staining (mean, .79%  .35%), but it was signiﬁcantlydermal and dermal parts of the skin biopsy samples from patients with GVHD
SCT. Bar graphs in the bottom 2 panels show the percentage of cells with double
nd PolþCD34þ in the skin biopsies obtained pre- (blue bar) and post- (red bar)
d by ANOVA; ns indicates not signiﬁcant.
Figure 4. Comparative percentage of cells that are PolþCD34þ, CD34þE-
cadherinþ, and PolþCD1aþ in patients with GVHD (group I), EM-like rash
with no GVHD (group II), and no rash (group III) studied pre-HSCT (blue bar)
and post-HSCT (red bar). *, **, and *** represent P values calculated by ANOVA;
ns indicates not signiﬁcant.
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was also true for PolþCD1aþ cells that were also detected at
minimal background levels in the baseline samples from 6 of
13 patients (mean, .76%  .4%), but were signiﬁcantly
increased (mean 7.9%  3%) in 10 of 13 patients at the time
that they developed GVHD (P ¼ .023 by ANOVA). Because
HSV infection favors the differentiation of CD34þ cells into
LC through increased expression of E-cadherin [28], thereby
facilitating skin repopulation [31], the pre- and post-HSCT
blood samples were also examined for CD34þE-cadherinþ
cells. Minimal background staining was seen in the pre-
HSCT samples (.6%  .3%) from 6 of 13 patients, but this
was increased to 5.3%  2.5% CD34þE-cadherinþ cells at the
time when they developed GVHD (P ¼ .05 by ANOVA).
Although the percentage of Polþ monocytes was similar
in the pre- and post-HSCT biopsies, 11 of 13 patients had
a relatively high percentage of circulating Polþ monocytes
(CD14þ) pre-HSCT (9.1%  3.5%) that signiﬁcantly increased
in 13 of 13 patients post-HSCT (32.2%  5.9%; P ¼ .002 by
ANOVA). This suggests that HSV infects both host and donor
CD14þ monocytes (pre- and post-HSCT, respectively), but
they do not directly contribute to skin lesion development.
By contrast, the presence of: (1) increased numbers of
circulating PolþCD34þ, PolþCD1aþ and CD34þE-cadherinþ
PBMC post-HSCT, and (2) both PolþCD34þ and PolþCD1aþ
cells in the GVHD skin, associates GVHD development with
LC generated from HSV-infected, likely donor, CD34þ PBMC.Group II (EM-Like Rash with No GVHD)
Skin ﬁndings
All 3 patients in this group had Polþ cells in the epidermis
(47.5%  23%) and dermis (8.1%  6.9%) and PolþCD34þ cells
in the dermis (3.1%  2.6%) at baseline (pre-HSCT), and they
decreased with time (4.1%  1.1%, 0 and 0, respectively post-
HSCT). However, the difference between the pre- and post-
HSCT ﬁndings was not statistically signiﬁcant. PolþCD1aþ,
PolþCD14þ, and PolþCD11bþ cells were not seen in the skin
whether pre- or post-HSCT (Table 2, Figure 3).Blood ﬁndings
Relatively low numbers of circulating PolþCD34þ,
CD34þE-Cadherinþ, and PolþCD1aþ PBMC (1% to 3.4%) and
somewhat higher numbers of PolþCD14þ PBMC were seen
in the blood samples from these patients pre- and post-HSCT
(Table 2, Figure 4). The percentage of PolþCD14þ cells was
higher in the pre-HSCT (26.6%  9.1%) than post-HSCT (4.3%
 3.5%) samples, underscoring the potential relevance of this
cell population with respect to clinical presentation, but the
difference was not statistically signiﬁcant (Table 2, Figure 4).
Collectively, the skin and blood data document the
difference between these patients and those in group I in
terms of their response to reactivated HSV. This conclusion is
supported by the signiﬁcant differences seen when
comparing the 2 groups for PolþCD34þ and PolþCD14þ (P>
.002) as well as CD34þEcadherinþ PBMC (P > .005) by the
exact nonparametric rank test. It is also supported by the
ﬁnding of signiﬁcant differences when using the nonpara-
metric rank test to compare the 2 groups with respect to Pol
expression in the post-HSCT skin (P ¼ .005 and P ¼ .0018 for
epidermis and dermis, respectively), but not when the
2 groups were compared for the pre-HSCT skin and blood.
Group III (No Rash)
Skin and Blood ﬁndings
Data are available for 16 of the 18 patients in this group.
Their skin samples (obtained at baseline) were negative
for Pol and Polþ PBMC (<.1%) and their blood samples
evidenced a low percentage of circulating PolþCD34þ and
PolþCD1aþ and a higher percentage of PolþCD14þ cells pre-
HSCT that were not signiﬁcantly changed post-HSCT
(Table 2; Figures 3 and 4).
DISCUSSION
The salient feature of the data presented in this report is
the ﬁnding of frequent HSV antigen in acute skin GVHD
lesions occurring post-HSCT and its association with
increased numbers of circulating antigenpositive CD34þ and
CD1aþ cells that also inﬁltrate the lesions. The following
comments seem pertinent with respect to these ﬁndings.
The timing of GVHD development in our patients
(range, 8 to 244 days; median, 26 days) is consistent with the
occurrence of acute GVHD around the time of myeloid
recovery and it may be associated with engraftment
syndrome, which shares a similar cytokine surge as that
seen in acute GVHD. Although the total number of studied
subjects is relatively small, our data establish a highly
signiﬁcant difference between the patients in the 3 groups in
terms of HSV antigen expression in the skin and PBMC
(Table 2), which is unlikely to change by the study of a larger
cohort. Given the limitations imposed by the restricted
availability of patient tissues and/or PBMC, the bulk of our
studies relied on immunohistochemistry, which is widely
used for virologic diagnosis of epithelial HSV lesions in the
clinical setting [35]. The high speciﬁcity of the Pol antibody is
established [8,14-18,22,23,30]. Our immunoblotting and
staining experiments conﬁrmed the presence of the Pol
protein in culture positive lesions and both Pol protein and
Pol DNA were seen in GVHD and HAEM lesions, but not in
normal skin. The ability of the Pol antibody to stain GVHD
tissue is not an artifact caused by the nonspeciﬁc recognition
of human antigens, because staining was not seen in the
group III patients. It is not due to nonspeciﬁc reactivity with
epitopes unique to some patients (notably those in group I),
because the skin tissues collected from the very same
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Staining is also not due to nonspeciﬁc recognition of a GVHD-
speciﬁc antigen because it was not seen in the extracuta-
neous GVHD lesions experienced by the very same patients.
We cannot exclude cross-reactivity with host antigens newly
expressed only in skin cells and PBMC, but there is no known
relationship between these 2 cell types that could explain
such a phenomenon. The staining data reﬂect expression of
the viral protein because post-HSCT biopsies were positive
for Pol DNA (determined by PCR) and Pol protein (deter-
mined by immunoblotting), although these were not seen in
normal skin from the same patients. The signiﬁcant increase
in the percentage of Polþ cells in the more severe GVHD
lesions from the same patients supports the correlation
between HSV and GVHD lesion development. A limitation of
our study is the lack of PCR-based conﬁrmation of HSV DNA
in the plasma, in order to determine virus reactivation during
conditioning. However, HSV DNAemia is limited to primary
severe infections and it cannot be detected in latency
reactivation [36].
The ﬁrst step in the development of acute GVHD is the
activation of host antigen presenting cells, resulting in
enhanced presentation of major and minor alloantigens to
donor T cells [1]. Virus-induced DC differentiation and its
role in T cell stimulation are well established. Infection of
blood monocytes with lethal inﬂuenza A, vesicular stoma-
titis, or vaccinia viruses induces DC differentiation within 18
hours postinfection and these CD16-CD83þ mature DCs
have enhanced capacity to activate T cells [32]. Reactivation
of CMV, Epstein-Barr virus, and HHV-6, -7 during the
immunosuppressive period pre- and post-allogeneic HSCT,
increases the risk of GVHD development [5], but the
contribution of reactivated HSV to GVHD development is
still unclear. We raised the possibility that HSV could
contribute to post-HSCT skin GVHD, because: (1) intracel-
lular HSV DNA activates DC through TLR9 binding [29]; and
(2) CD34þ cells can differentiate into LC when infected with
HSV and they contribute to HAEM development indepen-
dent of virus replication [28]. Conﬁrming our previous
conclusions [30], the post-HSCT GVHD biopsies from 8 of 15
and 6 of 13 patients in this cohort, respectively contained
PolþCD34þ and PolþCD1aþ cells that were not seen in the
pre-HSCT baseline skin. The CD34þ and CD1aþ cells did not
stain with VP5 antibody, consistent with their role in viral
DNA fragmentation [28]. The PolþCD34þ and PolþCD1aþ
cells in the GVHD biopsies are likely to be of donor origin
and reach the skin from the circulation, because the
percentages of these circulating cells were signiﬁcantly
elevated in the blood samples collected at the time of the
GVHD presentation relative to the pre-HSCT blood samples.
Although it would have been desirable to stain the donor
peripheral blood CD34þ cells to conﬁrm that they do not
express Pol, PBMC from normal subjects are known to be Pol
negative [18], as also conﬁrmed in our control subjects.
Interestingly, 11 of 13 patients had a relatively high
percentage of circulating Polþ monocytes (CD14þ) pre-
HSCT and it was signiﬁcantly increased post-HSCT, sug-
gesting that HSV activates both host and donor monocytes.
The increased numbers of circulating PolþCD14þ cells seen
post-HSCT might reﬂect ampliﬁcation of the host monocytes
that survived through transplantation, unrelated to the
infection of the donor cells. However, there was no signiﬁ-
cant increase in the percentage PolþCD14þ (and
PolþCD11bþ) cells in the GVHD biopsies as compared with
normal pre-HSCT skin.In group II patients, we observed relatively high levels of
Pol expression and PolþCD34þ cells in the pre-HSCT base-
line samples that decreased with time, potentially reﬂecting
the infection of host cells, which declined in quantity after
the conditioning regimen. Given their distinct presentation,
these patients may actually have HAEM. This interpretation
is supported by the shorter time to lesion development
relative to the GVHD lesions (median 16 versus 26 days,
respectively). However, additional studies are needed to
verify whether the lesions express the HAEM-associated
markers IFN-g, SP1, TGF-b, p21(waf1), and Hsp27 [22,23],
particularly since drug eruptions (which are positive for
tumor necrosis factor-alpha, but not IFN-g [22]) are not
uncommon in transplant recipients.
Our studywas initially designed to obtain second biopsies
from all patients regardless of their rash status. However, the
protocol was later amended because of ethical concerns after
negative-HSV ﬁndings in 3 patients who did not develop any
rash post transplantation (group III). Although the absence of
post-HSCT biopsies in these patients limits our ability to
verify that they did not have Polþ cells (including CD34þ and
CD1aþ) post-HSCT, this is unlikely, because normal skin was
free of Polþ cells in all the studied subjects. The absence of
increased Pol expression in blood CD34þ cells post-HSCT
provides indirect evidence of negative Pol expression in the
skin at that time.
Collectively, our data suggest that skin GVHD resembles
HAEM in its association with a nonreplicative (incomplete)
HSV infection that is associated with viral DNA fragmenta-
tion within infected CD34þ cells and the transportation of
the DNA fragments to the skin [8,14-20]. Because similar
histopathological criteria are used to identify GVHD and
reactive dermatoses that include HAEM, we cannot exclude
the possibility that the skin lesions experienced by the group
I patients and diagnosed as GVHD are actually virus-
associated erythematous lesions in the same family of
reactive dermatoses as HAEM. Further studies are needed
to better elucidate the role of HSV reactivation in acute
GVHD induction and verify the contribution of circulating
PolþCD34þ cells to this process. Additional information
about the expression of other HSV antigens and better deﬁ-
nition of the patients who do not develop GVHD post-HSCT
are particularly desirable. Still, the clinical implications of
our data are noteworthy. Based on the ﬁnding of a very high
proportion of patients with skin GVHD who express HSV
antigen resulting from nonreplicative infection, we raise the
question of whether or not current HSV prophylaxis inhibits
the HSV contribution. Because antiviral therapy targets virus
replication, which is not required for antigen expression by
viral DNA fragments, oral acyclovir therapy initiated 3 days
post-HSCT, when the virus has already had the opportunity
to infect CD34þ cells and stimulate reactive Tcells, is unlikely
to fully suppress the effects of HSV reactivation. However, it
is possible that a higher dose of acyclovir administered early
and perhaps by intravenous injection may inhibit virus
reactivation [33,34], thereby reducing the risk of infecting
circulating CD34þ cells and the associated incidence and
severity of skin GVHD.
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